Lipopolysaccharide (LPS) extracted from <em>Bacteroides vulgatus</em> effectively prevents LPS extracted from <em>Escherichia coli</em> from inducing epithelial‑mesenchymal transition

Li,Yuping; Xu,Mengdan; Zhai,Haiying; Yang,Changfu; Yang,Jiaotong; Ke,Zunli; Chen,Wanhao; Ou,Jiangqin; Sha,Zongge; Xiao,Qiaoqiao

doi:10.3892/mmr.2023.13082

Lipopolysaccharide (LPS) extracted from Bacteroides vulgatus effectively prevents LPS extracted from Escherichia coli from inducing epithelial‑mesenchymal transition

Authors:
- Yuping Li
- Mengdan Xu
- Haiying Zhai
- Changfu Yang
- Jiaotong Yang
- Zunli Ke
- Wanhao Chen
- Jiangqin Ou
- Zongge Sha
- Qiaoqiao Xiao
View Affiliations

Affiliations: Basic Medical School, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550025, P.R. China, Shizhen College, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550200, P.R. China, The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550000, P.R. China, The First Affiliated Hospital, Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou 550000, P.R. China
Published online on: September 4, 2023 https://doi.org/10.3892/mmr.2023.13082
Article Number: 195
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pathological epithelial‑mesenchymal transition (EMT) has been shown to fulfill a key role in the development and progression of a variety of lung diseases. It has been demonstrated that the inflammatory microenvironment is a decisive factor in inducing pathological EMT. Hexacylated lipopolysaccharide (LPS) [or proacylated lipopolysaccharide (P‑LPS), which functions as proinflammatory lipopolysaccharide] is one of the most effective Toll‑like receptor 4 (TLR4) agonists. Furthermore, the pentacylated and tetracylated form of lipopolysaccharide (or A‑LPS, which functions as anti‑inflammatory lipopolysaccharide) has been shown to elicit competitive antagonistic effects against the pro‑inflammatory activity of P‑LPS. At present, it remains unclear whether LPS extracted from Bacteroides vulgatus (BV‑LPS) can prevent LPS extracted from Escherichia coli (EC‑LPS) from inducing pathological EMT. In the present study, A549 cells and C57BL/6 mice lung tissue were both induced by EC‑LPS (P‑LPS) and BV‑LPS (A‑LPS), either alone or in combination. The anticipated anti‑inflammatory effects of BV‑LPS were analyzed by examining the lung coefficient, lung pathology, A549 cell morphology and expression levels both of the inflammatory cytokines, IL‑1β, IL‑6 and TNF‑α and of the EMT signature proteins, epithelial cadherin (E‑cadherin), α‑smooth muscle actin (α‑SMA) and vimentin. In addition, the expression levels of TLR4, bone morphogenic protein and activin membrane‑bound inhibitor (BAMBI) and Snail were detected and the possible mechanism underlying how BV‑LPS may prevent EC‑LPS‑induced EMT was analyzed. The results obtained showed that the morphology of the A549 cells was significantly polarized, the lung index was significantly increased, the alveolar structure was collapsed and the expression levels of IL‑1β, IL‑6, TNF‑α, α‑SMA, vimentin, TLR4 and Snail in both lung tissue and A549 cells were significantly increased, whereas those of E‑cadherin and BAMBI were significantly decreased. Treatment with BV‑LPS in combination with EC‑LPS was found to reverse these changes. In conclusion, the present study demonstrated that BV‑LPS is able to effectively prevent EC‑LPS‑induced EMT in A549 cells and in mouse lung tissue and furthermore, the underlying mechanism may be associated with inhibition of the TLR4/BAMBI/Snail signaling pathway.

View Figures

View References

1	Rout-Pitt N, Farrow N, Parsons D and Donnelley M: Epithelial mesenchymal transition (EMT): A universal process in lung diseases with implications for cystic fibrosis pathophysiology. Respir Res. 19:1362018. View Article : Google Scholar : PubMed/NCBI
2	Yang Y, Hu L, Xia H, Chen L, Cui S, Wang Y, Zhou T, Xiong W, Song L, Li S, et al: Resolvin D1 attenuates mechanical stretch-induced pulmonary fibrosis via epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol. 316:L1013–L1024. 2019. View Article : Google Scholar : PubMed/NCBI
3	Yang ZC, Qu ZH, Yi MJ, Shan YC, Ran N, Xu L and Liu XJ: MiR-448-5p inhibits TGF-β1-induced epithelial-mesenchymal transition and pulmonary fibrosis by targeting Six1 in asthma. J Cell Physiol. 234:8804–8814. 2019. View Article : Google Scholar : PubMed/NCBI
4	Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI
5	López-Novoa JM and Nieto MA: Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar : PubMed/NCBI
6	Fedele G, Nasso M, Spensieri F, Palazzo R, Frasca L, Watanabe M and Ausiello CM: Lipopolysaccharides from Bordetella pertussis and Bordetella parapertussis differently modulate human dendritic cell functions resulting in divergent prevalence of Th17-polarized responses. J Immunol. 181:208–216. 2008. View Article : Google Scholar : PubMed/NCBI
7	Park BS, Song DH, Kim HM, Choi BS, Lee H and Lee JO: The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature. 458:1191–1195. 2009. View Article : Google Scholar : PubMed/NCBI
8	Lin TL, Shu CC, Chen YM, Lu JJ, Wu TS, Lai WF, Tzeng CM, Lai HC and Lu CC: Like Cures Like: Pharmacological activity of anti-inflammatory lipopolysaccharides from gut microbiome. Front Pharmacol. 11:5542020. View Article : Google Scholar : PubMed/NCBI
9	Cardinelli CS, Sala PC, Alves CC, Torrinhas RS and Waitzberg DL: Influence of intestinal microbiota on body weight gain: A narrative review of the literature. Obes Surg. 25:346–353. 2015. View Article : Google Scholar : PubMed/NCBI
10	Brown GC: The endotoxin hypothesis of neurodegeneration. J Neuroinflammation. 16:1802019. View Article : Google Scholar : PubMed/NCBI
11	He Z, Zhu Y and Jiang H: Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: An experimental study. Respir Res. 10:1262009. View Article : Google Scholar : PubMed/NCBI
12	Hirschfeld M, Ma Y, Weis JH, Vogel SN and Weis JJ: Cutting edge: Repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J Immunol. 165:618–622. 2000. View Article : Google Scholar : PubMed/NCBI
13	d'Hennezel E, Abubucker S, Murphy LO and Cullen TW: Total lipopolysaccharide from the human gut microbiome silences toll-like receptor signaling. mSystems. 2:e00046–17. 2017.PubMed/NCBI
14	Ding Z, Wu X, Wang Y, Ji S, Zhang W, Kang J, Li J and Fei G: Melatonin prevents LPS-induced epithelial-mesenchymal transition in human alveolar epithelial cells via the GSK-3β/Nrf2 pathway. Biomed Pharmacother. 132:1108272020. View Article : Google Scholar : PubMed/NCBI
15	Chen D, Qiu YB, Gao ZQ, Wu YX, Wan BB, Liu G, Chen JL, Zhou Q, Yu RQ and Pang QF: Sodium propionate attenuates the lipopolysaccharide-induced epithelial-mesenchymal transition via the PI3K/Akt/mTOR signaling pathway. J Agric Food Chem. 68:6554–6563. 2020. View Article : Google Scholar : PubMed/NCBI
16	Zhang YQ, Liu YJ, Mao YF, Dong WW, Zhu XY and Jiang L: Resveratrol ameliorates lipopolysaccharide-induced epithelial mesenchymal transition and pulmonary fibrosis through suppression of oxidative stress and transforming growth factor-β1 signaling. Clin Nutr. 34:752–760. 2015. View Article : Google Scholar : PubMed/NCBI
17	Tang S, Jiang X, Wu L, Chen S, Chen L, Jiang J, Yan P, Wang F, Tu K, Wang D, et al: Toll-like receptor 4 shRNA attenuates lipopolysaccharide-induced epithelial-mesenchymal transition of intrahepatic biliary epithelial cells in rats. Biomed Pharmacother. 107:1210–1217. 2018. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta DeltaC(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Liu W, Sun T and Wang Y: Integrin αvβ6 mediates epithelial-mesenchymal transition in human bronchial epithelial cells induced by lipopolysaccharides of Pseudomonas aeruginosa via TGF-β1-Smad2/3 signaling pathway. Folia Microbiol (Praha). 65:329–338. 2020. View Article : Google Scholar : PubMed/NCBI
20	Gong JH, Cho IH, Shin D, Han SY, Park SH and Kang YH: Inhibition of airway epithelial-to-mesenchymal transition and fibrosis by kaempferol in endotoxin-induced epithelial cells and ovalbumin-sensitized mice. Lab Invest. 94:297–308. 2014. View Article : Google Scholar : PubMed/NCBI
21	Li H, Li J, Zhang G, Da Q, Chen L, Yu S, Zhou Q, Weng Z, Xin Z, Shi L, et al: HMGB1-Induced p62 overexpression promotes snail-mediated epithelial-mesenchymal transition in glioblastoma cells via the degradation of GSK-3β. Theranostics. 9:1909–1922. 2019. View Article : Google Scholar : PubMed/NCBI
22	Lim KH and Staudt LM: Toll-like receptor signaling. Cold Spring Harb Perspect Biol. 5:a0112472013. View Article : Google Scholar : PubMed/NCBI
23	He Y, Ou Z, Chen X, Zu X, Liu L, Li Y, Cao Z, Chen M, Chen Z, Chen H, et al: LPS/TLR4 signaling enhances TGF-β response through downregulating BAMBI during prostatic hyperplasia. Sci Rep. 6:270512016. View Article : Google Scholar : PubMed/NCBI
24	Kaufhold S and Bonavida B: Central role of Snail1 in the regulation of EMT and resistance in cancer: A target for therapeutic intervention. J Exp Clin Cancer Res. 33:622014. View Article : Google Scholar : PubMed/NCBI
25	Yoshida N, Emoto T, Yamashita T, Watanabe H, Hayashi T, Tabata T, Hoshi N, Hatano N, Ozawa G, Sasaki N, et al: Bacteroides vulgatus and Bacteroides dorei Reduce gut microbial lipopolysaccharide production and inhibit atherosclerosis. Circulation. 138:2486–2498. 2018. View Article : Google Scholar : PubMed/NCBI
26	Steimle A, Michaelis L, Di Lorenzo F, Kliem T, Münzner T, Maerz JK, Schäfer A, Lange A, Parusel R, Gronbach K, et al: Weak agonistic LPS restores intestinal immune homeostasis. Mol Ther. 27:1974–1991. 2019. View Article : Google Scholar : PubMed/NCBI
27	Zhao L, Yang R, Cheng L, Wang M, Jiang Y and Wang S: LPS-induced epithelial-mesenchymal transition of intrahepatic biliary epithelial cells. J Surg Res. 171:819–825. 2011. View Article : Google Scholar : PubMed/NCBI
28	Pulskens WP, Rampanelli E, Teske GJ, Butter LM, Claessen N, Luirink IK, van der Poll T, Florquin S and Leemans JC: TLR4 promotes fibrosis but attenuates tubular damage in progressive renal injury. J Am Soc Nephrol. 21:1299–1308. 2010. View Article : Google Scholar : PubMed/NCBI
29	Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, et al: Toll-like receptor 4 signaling augments transforming growth factor-β responses: A novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am J Pathol. 182:192–205. 2013. View Article : Google Scholar : PubMed/NCBI
30	Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA and Schwabe RF: TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 13:1324–1332. 2007. View Article : Google Scholar : PubMed/NCBI
31	Lutz M and Knaus P: Integration of the TGF-beta pathway into the cellular signalling network. Cell Signal. 14:977–988. 2002. View Article : Google Scholar : PubMed/NCBI
32	Chen J, Bush JO, Ovitt CE, Lan Y and Jiang R: The TGF-beta pseudoreceptor gene Bambi is dispensable for mouse embryonic development and postnatal survival. Genesis. 45:482–486. 2007. View Article : Google Scholar : PubMed/NCBI
33	Zhang YE: Non-Smad pathways in TGF-beta signaling. Cell Res. 19:128–139. 2009. View Article : Google Scholar : PubMed/NCBI
34	Sisto M, Lorusso L, Ingravallo G, Ribatti D and Lisi S: TGFβ1-Smad canonical and -Erk noncanonical pathways participate in interleukin-17-induced epithelial-mesenchymal transition in Sjögren's syndrome. Lab Invest. 100:824–836. 2020. View Article : Google Scholar : PubMed/NCBI
35	Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G and Ten Dijke P; IT-LIVER Consortium, : TGF-β signalling and liver disease. FEBS J. 283:2219–2232. 2016. View Article : Google Scholar : PubMed/NCBI
36	Willis BC and Borok Z: TGF-beta-induced EMT: Mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 293:L525–L534. 2007. View Article : Google Scholar : PubMed/NCBI
37	Prud'homme GJ: Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease and therapeutic considerations. Lab Invest. 87:1077–1091. 2007. View Article : Google Scholar : PubMed/NCBI
38	Heldin CH and Moustakas A: Signaling receptors for TGF-β family members. Cold Spring Harb Perspect Biol. 8:a0220532016. View Article : Google Scholar : PubMed/NCBI
39	Wrighton KH, Lin X and Feng XH: Phospho-control of TGF-beta superfamily signaling. Cell Res. 19:8–20. 2009. View Article : Google Scholar : PubMed/NCBI
40	Hill CS: Transcriptional control by the SMADs. Cold Spring Harb Perspect Biol. 8:a0220792016. View Article : Google Scholar : PubMed/NCBI
41	Brandl M, Seidler B, Haller F, Adamski J, Schmid RM, Saur D and Schneider G: IKK(α) controls canonical TGF(ß)-SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in panc1 cells. J Cell Sci. 123((Pt 24)): 4231–4239. 2010. View Article : Google Scholar : PubMed/NCBI
42	Sisto M, Lorusso L, Ingravallo G, Tamma R, Ribatti D and Lisi S: The TGF-1 signaling pathway as an attractive target in the fibrosis pathogenesis of Sjögren's Syndrome. Mediators Inflamm. 2018:19659352018. View Article : Google Scholar : PubMed/NCBI
43	Chen XF, Zhang HJ, Wang HB, Zhu J, Zhou WY, Zhang H, Zhao MC, Su JM, Gao W, Zhang L, et al: Transforming growth factor-β1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol Biol Rep. 39:3549–3556. 2012. View Article : Google Scholar : PubMed/NCBI